Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

RFrag Synthesis and Function of Non-Canonical RNA Fragments

Coordinator
Ludwig-Maximilians-Universitaet Muenchen, Germany
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101265008

What the project is doing

In the project's own words, from its summary on CORDIS.

RNA lies at the core of the central dogma of molecular biology. It can both store genetic information and catalyse biochemical reactions. An often-overlooked property is that it contains next to A, G, C, and U, approximately 170 different non-canonical nucleosides. Transfer RNAs (tRNAs), as the central adaptor molecules for translating, harbour the highest number of these non-canonical nucleosides. A recent surprising discovery revealed that tRNAs are cleaved by, in part, unknown RNases into smaller fragments, referred to as tsRNAs, which keep the non-canonical nucleosides.

The functions of this entirely novel class of RNA molecules remain unknown. Our first goal is to prepare phosphoramidite building blocks for non-canonical nucleosides and to synthesize tsRNAs. Although all available knowledge about tsRNAs has been obtained using synthetic RNAs that lack modified nucleosides, the data suggest that their primary function is to stimulate the immune system to enhance for example anticancer responses.

Consequently, we plan to focus our synthetic efforts at evaluating the immunological effects of tsRNAs. This aim is further supported by the seminal discovery of Weissman and Kariko, who demonstrated that the presence of non-canonical nucleosides, such as pseudouridine, in mRNA profoundly modulates immune recognition. The second goal of the study is to employ the synthetic tsRNAs, containing the respective embedded non-canonical nucleosides, to investigate how these fragments are processed by specific RNases.

We will analyse how tsRNAs, or their secondary cleavage products, activate immune responses. Furthermore, we plan to identify and characterize the enzymes involved in these processing pathways. Finally, we will study tsRNAs derived from pathogenic bacteria following infection, focusing on those carrying pathogen-specific non-canonical nucleosides. We hypothesize that these structures will elicit particularly strong immune responses.

Topics

Who is involved

OrganisationCityCountryRole
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS